Ginsenoside Rg3 achieves therapeutic effects on hepatocellular carcinoma by blocking the EGF-epidermal growth factor receptor (EGFR)-extracellular signal-regulated kinase 1/2 (ERK1/2)-HIF-1α signaling axis, blocking the expression of NHE1 (88). The gene discussed is EGFR; the disease is hepatocellular carcinoma.